查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1517645

孟魯司特鈉市場 - 按產品類型（無定形孟魯司特鈉、結晶孟魯司特鈉）劑型（片劑、口服溶液）、應用（氣喘、過敏性鼻炎、蕁麻疹）、配銷通路-全球預測（2024 - 2032）

Montelukast Sodium Market - By Product Type (Montelukast Sodium Amorphous, Montelukast Sodium Crystalline) Dosage Form (Tablets, Oral Solutions), Application (Asthma, Allergic Rhinitis, Urticaria), Distribution Channel - Global Forecast (2024 - 2032)
出版日期: | 出版商: Global Market Insights Inc. | 英文 190 Pages | 商品交期: 2-3個工作天內

價格
簡介目錄

由於全球氣喘和過敏性鼻炎等呼吸系統疾病盛行率不斷上升，孟魯司特鈉市場規模預計 2024 年至 2032 年複合年成長率為 11.4%。根據美國國立衛生研究院的數據，全球約有 4 億人受到過敏性鼻炎的影響。

污染的增加和​​生活方式的改變導致人們擴大使用呼吸系統藥物來改善症狀。此外，研究人員正在發現治療慢性阻塞性肺病和支氣管炎等呼吸道疾病的藥物的新用途，從而導致產品需求增加。製藥公司和研究機構之間的合作也推動了市場的成長。

孟魯司特鈉產業按產品類型、劑型、應用、配銷通路和地區細分。

就劑型而言，由於口服溶液的便利性、易於給藥和增強的患者依從性，預計到 2032 年，口服溶液領域的市場規模將大幅成長。以患者為中心的醫療保健強調口服溶液作為片劑或顆粒劑的替代品，特別是對於兒童和老年人，為吞嚥困難的人提供精確的劑量控制。口服溶液還可以提供更好的口味，並提高患者在醫療保健環境中的接受度和依從性。

過敏性鼻炎應用領域的孟魯司特鈉產業將在 2024 年至 2032 年期間產生可觀的收入，這得益於藥物在管理呼吸系統疾病相關症狀方面的效率。過敏性鼻炎是一種常見疾病，會導致鼻塞、打噴嚏和眼睛發癢等症狀。為此，使用孟魯司特鈉，因為它針對白三烯來緩解症狀並改善患者的呼吸健康。

由於環境污染、生活方式改變和遺傳傾向導致呼吸系統疾病盛行率上升，亞太地區孟魯司特鈉產業預計到 2032 年將顯著成長。亞洲的城市成長和工業擴張正在惡化空氣品質。政府對改善衛生基礎設施和擴大藥物取得的支持不斷增加也將刺激區域市場的成長。

目錄

第 1 章：方法與範圍

第 2 章：執行摘要

第 3 章：產業洞察

  • 產業生態系統分析
  • 產業影響力
    • 成長動力
      • 呼吸道疾病盛行率增加
      • 藥物輸送的進展
      • 提高認知和診斷
    • 產業陷阱與挑戰
      • 副作用和安全問題
      • 替代治療方案
  • 成長潛力分析
  • 監管環境
  • 波特的分析
  • 佩斯特爾分析

第 4 章：競爭格局

  • 介紹
  • 公司市佔率分析
  • 競爭定位矩陣
  • 戰略展望矩陣

第 5 章：市場估計與預測：按產品類型，2021 - 2032 年

  • 主要趨勢
  • 無定形孟魯司特鈉
  • 孟魯司特鈉結晶

第 6 章：市場估計與預測：按劑型，2021 - 2032

  • 主要趨勢
  • 平板電腦
  • 口服溶液

第 7 章：市場估計與預測：按應用分類，2021 - 2032

  • 主要趨勢
  • 氣喘
  • 過敏性鼻炎
  • 蕁麻疹
  • 其他應用

第 8 章：市場估計與預測：按配銷通路分類，2021 - 2032 年

  • 主要趨勢
  • 醫院藥房
  • 零售藥局
  • 網路藥局

第 9 章：市場估計與預測：按地區，2021 - 2032

  • 主要趨勢
  • 北美洲
    • 美國
    • 加拿大
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 西班牙
    • 義大利
    • 荷蘭
    • 歐洲其他地區
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 韓國
    • 亞太地區其他地區
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 阿根廷
    • 拉丁美洲其他地區
  • 中東和非洲
    • 沙烏地阿拉伯
    • 南非
    • 阿拉伯聯合大公國
    • 中東和非洲其他地區

第 10 章：公司簡介

  • Apotex Inc.
  • Cipla Limited
  • Dr. Reddy's Laboratories Ltd.
  • Intas Pharmaceuticals Ltd
  • Merck & Co., Inc.
  • Morepen Laboratories Limited
  • Mylan N.V.
  • Sandoz AG
  • Sanofi
  • Sun Pharma Industries Limited.
  • Teva Pharmaceutical Industries Limited
簡介目錄
Product Code: 9309

Montelukast sodium market size is estimated to register 11.4% CAGR between 2024 and 2032, backed by the rising prevalence of respiratory diseases, such as asthma and allergic rhinitis worldwide. As per the National Institute of Health, around 400 million people globally are affected with allergic rhinitis worldwide.

Increased pollution and changing lifestyles are leading to the increased use of respiratory medications to improve symptoms. Moreover, researchers are uncovering new uses for drugs in treating respiratory diseases likes COPD and bronchitis, leading to increased product demand. Collaborations between pharmaceutical companies and research institutes are also driving the market growth.

The montelukast sodium industry is segmented into product type, dosage form, application, distribution channel and region.

With respect to dosage form, the market size from the oral solutions segment is anticipated to witness substantial growth through 2032, owing to their convenience, ease of administration, and enhanced patient compliance. Patient-centered healthcare is emphasizing oral solutions as an alternative to tablets or granules, particularly for children and the elderly for offering precise dose control for those who have difficulty swallowing. Oral solutions also provide better taste as well as increased patient acceptance and compliance in healthcare settings.

Montelukast sodium industry from the allergic rhinitis application segment will generate notable revenue during 2024-2032, backed by the efficiency of drugs in managing symptoms related to respiratory conditions. Allergic rhinitis is a common condition causing symptoms like nasal congestion, sneezing, and itchy eyes. To that end, montelukast sodium is used as it targets leukotrienes to relieve symptoms and improve respiratory health for sufferers.

Asia Pacific montelukast sodium industry is slated to witness a significant growth rate through 2032, attributed to the rising prevalence of respiratory diseases due to environmental pollution, changing lifestyles, and genetic predispositions. Urban growth and industrial expansion in Asia are deteriorating air quality. The growing government support for improving health infrastructure and expanding access to medication will also stimulate the regional market growth.

Table of Contents

Chapter 1 Methodology & Scope

  • 1.1 Market scope & definitions
  • 1.2 Research design
    • 1.2.1 Research approach
    • 1.2.2 Data collection methods
  • 1.3 Base estimates & calculations
    • 1.3.1 Base year calculation
    • 1.3.2 Key trends for market estimation
  • 1.4 Forecast model
  • 1.5 Primary research and validation
    • 1.5.1 Primary sources
    • 1.5.2 Data mining sources

Chapter 2 Executive Summary

  • 2.1 Industry 360-degree synopsis

Chapter 3 Industry Insights

  • 3.1 Industry ecosystem analysis
  • 3.2 Industry impact forces
    • 3.2.1 Growth drivers
      • 3.2.1.1 Increasing prevalence of respiratory diseases
      • 3.2.1.2 Advancements in drug delivery
      • 3.2.1.3 Growing awareness and diagnosis
    • 3.2.2 Industry pitfalls & challenges
      • 3.2.2.1 Side effects and safety concerns
      • 3.2.2.2 Alternative treatment options
  • 3.3 Growth potential analysis
  • 3.4 Regulatory landscape
  • 3.5 Porter's analysis
  • 3.6 Pestel analysis

Chapter 4 Competitive Landscape, 2023

  • 4.1 Introduction
  • 4.2 Company market share analysis
  • 4.3 Competitive positioning matrix
  • 4.4 Strategy outlook matrix

Chapter 5 Market Estimates and Forecast, By Product Type, 2021 - 2032 ($ Mn)

  • 5.1 Key trends
  • 5.2 Montelukast sodium amorphous
  • 5.3 Montelukast sodium crystalline

Chapter 6 Market Estimates and Forecast, By Dosage Form, 2021 - 2032 ($ Mn)

  • 6.1 Key trends
  • 6.2 Tablets
  • 6.3 Oral solutions

Chapter 7 Market Estimates and Forecast, By Application, 2021 - 2032 ($ Mn)

  • 7.1 Key trends
  • 7.2 Asthma
  • 7.3 Allergic rhinitis
  • 7.4 Urticaria
  • 7.5 Other applications

Chapter 8 Market Estimates and Forecast, By Distribution Channel, 2021 - 2032 ($ Mn)

  • 8.1 Key trends
  • 8.2 Hospital pharmacies
  • 8.3 Retail pharmacies
  • 8.4 Online pharmacies

Chapter 9 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

  • 9.1 Key trends
  • 9.2 North America
    • 9.2.1 U.S.
    • 9.2.2 Canada
  • 9.3 Europe
    • 9.3.1 Germany
    • 9.3.2 UK
    • 9.3.3 France
    • 9.3.4 Spain
    • 9.3.5 Italy
    • 9.3.6 Netherlands
    • 9.3.7 Rest of Europe
  • 9.4 Asia Pacific
    • 9.4.1 Japan
    • 9.4.2 China
    • 9.4.3 India
    • 9.4.4 Australia
    • 9.4.5 South Korea
    • 9.4.6 Rest of Asia Pacific
  • 9.5 Latin America
    • 9.5.1 Brazil
    • 9.5.2 Mexico
    • 9.5.3 Argentina
    • 9.5.4 Rest of Latin America
  • 9.6 Middle East And Africa
    • 9.6.1 Saudi Arabia
    • 9.6.2 South Africa
    • 9.6.3 UAE
    • 9.6.4 Rest of Middle East and Africa

Chapter 10 Company Profiles

  • 10.1 Apotex Inc.
  • 10.2 Cipla Limited
  • 10.3 Dr. Reddy's Laboratories Ltd.
  • 10.4 Intas Pharmaceuticals Ltd
  • 10.5 Merck & Co., Inc.
  • 10.6 Morepen Laboratories Limited
  • 10.7 Mylan N.V.
  • 10.8 Sandoz AG
  • 10.9 Sanofi
  • 10.10 Sun Pharma Industries Limited.
  • 10.11 Teva Pharmaceutical Industries Limited